FDA’s Drug Price Push in Biosimilar Plan Hinges on Other Reforms

The FDA’s effort to curb high drug costs by accelerating approvals of cheaper medicines similar to expensive biologics will need other policy reforms to boost access to the biosimilars, drug pricing experts say.